{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-031468","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2026-09-29T20:19:02+00:00","discovered_at":"2026-09-29T20:20:00.262453+00:00","generated_at":"2026-10-12T13:50:10.117807+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Apyx Medical reports Renuvion study showing 30% elastin increase and 34% inflammation reduction at Day 180","bullets":["Study published in Plastic and Reconstructive Surgery — Global Open evaluated Renuvion helium plasma RF on skin quality; n=6 completed Day 180.","Treated tissue showed 30% increase in elastin fiber density and 55% increase in elastin staining intensity vs control.","Treated tissue had 34% reduction in inflammation and 27% increase in elastin expression incidence vs untreated control.","100% of participants reported improvement, satisfaction, and would recommend; 100% showed physician- and patient-assessed aesthetic improvement.","CEO Charlie Goodwin said findings support Renuvion's biological basis and that Renuvion should be part of every liposuction procedure."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-031468","json":"https://secwatch.observer/filing/0001437749-26-031468.json","markdown":"https://secwatch.observer/filing/0001437749-26-031468.md","text":"https://secwatch.observer/filing/0001437749-26-031468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000143774926031468/0001437749-26-031468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000143774926031468/apyx20260929_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:50:10.117807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}